Cypress Bioscience, Inc. (NASDAQ: CYPD) recently publicized that Sabrina Martucci Johnson, the Company’s Chief Operating Officer and Chief Financial Officer, will be presenting at Baird's 2009 Health Care Conference on September 9, 2009.
Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.
Sign Up for our Free Stock Newsletter
The Baird conference is being held at the Four Seasons Hotel in New York, NY. Ms. Johnson is scheduled to present on Wednesday, September 9th at 11:00 a.m. Eastern Time. A replay of the presentation will be available on the Cypress Bioscience website. Cypress Bioscience, Inc. provides therapeutics and personalized medicine services, facilitating improved and individualized patient care. Cypress addresses the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders such as fibromyalgia and rheumatoid arthritis. This approach to improving patient care creates a unique partnership with physicians. Current products include Savella™ (milnacipran HCI) and the Avise PG(SM) and Avise MCV(SM) therapeutic monitoring, diagnostic and prognostic tests for rheumatoid arthritis. With our acquisition in March 2008 of Proprius Pharmaceuticals, we expanded our strategy to provide personalized medicine services in the field of rheumatology. Personalized medicine services are tests that provide physicians with actionable information to help manage and optimize their patients’ care. These testing services are performed exclusively at our CLIA certified, CAP accredited clinical reference laboratory in San Diego. Our first two personalized medicine services are Avise PG and Avise MCV. We also have a number of proof of concept stage therapeutic and personalized medicine candidates in development. We continue to evaluate various other potential strategic transactions, including the acquisition of products, product candidates, technologies and companies.
Sign up for Today for our free Wall Street Grand newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Wall Street Grand
Wall Street Grand is the best investor relations company on the web. From Research Reports to Stock Profiles, we give you everything you need to make the best investment decisions daily. Each of our Featured Investment Opportunities hold premium characteristics to succeed even our own expectations making us the best kept secret of Wall Street.
To feature a company on our web site please contact us at the email listed below.
Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. Please click here to read the full disclaimer.
